Sichenzia Ross Friedman Ference LLP Advises DelMar Pharmaceuticals on $2.5M Registered Direct Offering
August 4, 2015 – Press Release – New York, NY – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the Firm has represented DelMar Pharmaceuticals, Inc. (OTCQX: DMPI), a biopharmaceutical company focused on developing and commercializing cancer therapies, in a registered direct offering. DelMar accepted subscriptions from institutional and accredited investors and approximately 4.0 million common stock and warrants for an aggregate price of $2.5 million. Each common share had a purchase price of $0.60 per share. The warrants had an exercise price of $0.75 per share.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Gregory Sichenzia, David Manno and Associate Jeffrey Cahlon.
- Sichenzia Ross Ference LLP Represents Lexaria Bioscience Corp. in Close of $11 Million Underwritten Public Offering and NASDAQ Uplisting - January 15, 2021
- Partner Andrew M.J. Bernstein to Present CLE on “Preparing Your Client to Testify Before a Grand Jury” for Lawline - January 11, 2021
- Sichenzia Ross Ference LLP Represents KULR Technology Group, Inc. in $8.0 Million Registered Direct Offering - January 4, 2021